Keyword Connections

ranibizumab

Journals

1

1 Trials

Research Groups

0

No Research Group Connected

Bibliographies

32

1 StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial.

2 ranibizumab with transpupillary thermotherapy for clinical efficacy in wet age-related macular degeneration

3 distant metastatic retinoblastoma without central nervous system involvement

4 study on the change of retinal thickness and choroidal thickness and correlative factors for macular edema after ranibizumab injection

5 effects of three consecutive monthly intravitreal injection of ranibizumab for polypoidal choroidal vasculopathy in korea

6 ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance

7 combined approach to the surgical treatment of patients with prolifera-tive stage of diabetic retinopathy

8 an unusual case of self-inflicted multiple needles injuries to eye

9 immediate sequential bilateral intravitreal injections: an indian perspective

10 Intestinal perforation after intravitreal low dose ranibizumab injection for the treatment of type 1 retinopathy of prematurity: A case report

11 [Re-treatment guideline of ranibizumab (genetical recombination) in the maintenance phase].

12 Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

13 Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study.

14 Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial.

15 Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.

16 Visual Performance in Patients with Neovascular Age-Related Macular Degeneration Undergoing Treatment with Intravitreal Ranibizumab

17 Visual performance in patients with neovascular age-related macular degeneration undergoing treatment with intravitreal ranibizumab

18 intravitreal ranibizumab and bevacizumab for the treatment of nonsubfoveal choroidal neovascularization in age-related macular degeneration ranibizumab e bevacizumab intravítreo no tratamento da neovascularização de coróide extrafoveal da degeneração macular relacionada à idade

19 ranibizumab in patients with dense cataract and proliferative diabetic retinopathy with rubeosis

20 daño renal asociado a la administración intravítrea de ranibizumab

21 a novel machine learning algorithm to automatically predict visual outcomes in intravitreal ranibizumab-treated patients with diabetic macular edema

22 a comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (macugen), ranibizumab (lucentis) and bevacizumab (avastin)

23 intravitreal ranibizumab for stage iv proliferative sickle cell retinopathy: a first case report

24 foveal exudative macroaneurysm treated with intravitreal ranibizumab

25 antiproliferative, apoptotic, and autophagic activity of ranibizumab, bevacizumab, pegaptanib, and aflibercept on fibroblasts: implication for choroidal neovascularization

26 conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab

27 prognostic factors of early morphological response to treatment with ranibizumab in patients with wet age-related macular degeneration

28 evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab

29 long-term visual outcome in wet age-related macular degeneration patients depending on the number of ranibizumab injections

30 comparisons of efficacy of intravitreal aflibercept and ranibizumab in eyes with diabetic macular edema

31 visual outcomes of age-related macular degeneration patients undergoing intravitreal ranibizumab monotherapy in an urban population

32 Short-term reactivation of retinopathy of prematurity following primary ranibizumab treatment.